UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For
September 11, 2007
Commission
File Number: 000-51310
XTL
Biopharmaceuticals Ltd.
(Translation
of registrant's name into English)
711
Executive Blvd., Suite Q
Valley
Cottage, New York 10989
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F
x Form
40-F
o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form,
the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes
o No
x
If
“Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
N/A
Reminder:
XTL to Hold a Conference Call Today at 8:30 am EDT to Discuss the Phase IIb
Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic
Pain
Valley
Cottage, New York, September 11, 2007 -
XTL
Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) will hold a
conference call today, September 11, 2007, at 8:30 a.m. EDT to discuss the
Phase
IIb clinical trial of Bicifadine for the treatment of diabetic neuropathic
pain
that was initiated yesterday.
Hosting
the call will be Ron Bentsur, XTL’s Chief Executive Officer. Participating on
the call will be two distinguished members of the diabetic neuropathic pain
clinical community: Dr. Christine Sang, Director of Translational Pain Research
at the Brigham and Women’s Hospital, Harvard Medical School, and Chair of XTL’s
Scientific Advisory Board; and Dr. Andrew Boulton, Professor of Medicine
at the
Diabetes Research Institute, University of Miami, and at the University of
Manchester in the United Kingdom, Chair of the American Diabetes Association
Foot Care Interest Group, and a co-lead investigator in the Bicifadine study.
In
order
to participate in the conference call, please call +1-877-502-9272 (in the
United States), +1-913-981-5581 (outside the United States), call in passcode:
2040477. An audio recording of the conference call will be available for
replay
by calling +1-888-203-1112 (in the United States), +1-719-457-0820 (outside
the
United States), replay passcode 2040477, for a period of 45 days after the
call.
ABOUT
XTL BIOPHARMACEUTICALS LTD.
XTL
Biopharmaceuticals Ltd. (“XTL”) is engaged in the development of therapeutics
for the treatment of neuropathic pain and hepatitis C. XTL is developing
Bicifadine, a serotonin and norepinephrine reuptake inhibitor, for the treatment
of diabetic neuropathic pain. XTL is also developing several novel pre-clinical
hepatitis C small molecule inhibitors. XTL also has an active in-licensing
and acquisition program designed to identify and acquire additional drug
candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock
Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).
Contact:
Ron
Bentsur, Chief Executive Officer
Tel:
+1-(845)-267-0707 ext. 225
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | ||
| |
|
|
| Date: September 11, 2007 | By: | /s/ Bill Kessler |
|
Bill Kessler |
||
| Director of Finance | ||